Weidmann E, Whiteside T L, Giorda R, Herberman R B, Trucco M
Department of Pathology, University of Pittsburgh School of Medicine, Pennsylvania.
Cancer Res. 1992 Nov 1;52(21):5913-20.
To determine a possibly restricted T-cell receptor (TCR) repertoire in tumor-infiltrating lymphocytes (TIL) in response to tumor-associated antigens in patients with hepatocellular carcinoma (HCC), freshly isolated TIL (n = 5) and peripheral blood lymphocytes (PBL; n = 6; 3 paired with TIL) were studied for expression of TCR variable (V) beta regions. RNA purified from TIL or PBL was reverse-transcribed into complementary DNA. This complementary DNA was amplified by quantitative polymerase chain reaction with 22 primers specific for 20 TCR V beta gene families and a 3' constant (C) beta primer. As a reference for later quantitation, a fragment of TCR C alpha was coamplified with each V beta region. Using 32P-labeled 3' primers, the percentage of total V beta expression was calculated by measuring the cpm of each of the amplified products. In contrast to PBL of 6 control, healthy individuals, whose range of expression of each TCR V beta gene varied from 0 to 13%, the expression of some V beta genes in HCC TIL was as high as 33%, indicating a restricted TCR V beta usage in HCC TIL. When polymerase chain reaction-amplified complementary DNAs of the V beta 1 or V beta 3 genes obtained from two TIL preparations were cloned and sequenced, the same rearrangements were found in the majority of DNA clones. The particular V beta genes that were over- or underrepresented in TIL varied among the patients. In 3 of 6 PBL and 3 of 5 TIL, the V beta 3 gene was expressed with a relatively high frequency. The V beta 4 gene expression was consistently low in patients' TIL or PBL. In 3 paired PBL and TIL, V beta expression was similar. In 5 of 6 cases, HCC PBL had different TCR V beta frequencies from those seen in normal PBL. This analysis of TCR V beta usage in freshly isolated TIL and in PBL indicated that T-lymphocytes in patients with HCC might have restricted immunological reactivity and that V beta 3-restricted TIL might represent antitumor effector cells.
为了确定肝细胞癌(HCC)患者肿瘤浸润淋巴细胞(TIL)中针对肿瘤相关抗原的可能受限的T细胞受体(TCR)库,对新鲜分离的TIL(n = 5)和外周血淋巴细胞(PBL;n = 6;其中3例与TIL配对)进行了TCR可变(V)β区域表达的研究。从TIL或PBL中纯化的RNA被逆转录成互补DNA。该互补DNA通过定量聚合酶链反应,使用针对20个TCR Vβ基因家族的22种引物和一个3'恒定(C)β引物进行扩增。作为后续定量的参考,TCR Cα片段与每个Vβ区域共同扩增。使用32P标记的3'引物,通过测量每个扩增产物的cpm来计算总Vβ表达的百分比。与6名对照健康个体的PBL不同,其每个TCR Vβ基因的表达范围从0到13%,HCC TIL中某些Vβ基因的表达高达33%,表明HCC TIL中TCR Vβ的使用受限。当对从两份TIL制剂中获得的Vβ1或Vβ3基因的聚合酶链反应扩增的互补DNA进行克隆和测序时,在大多数DNA克隆中发现了相同的重排。TIL中表达过高或过低的特定Vβ基因在患者之间有所不同。在6例PBL中的3例和5例TIL中的3例中,Vβ3基因以相对较高的频率表达。Vβ4基因在患者的TIL或PBL中的表达一直较低。在3对配对的PBL和TIL中,Vβ表达相似。在6例中的5例中,HCC PBL的TCR Vβ频率与正常PBL中的不同。对新鲜分离的TIL和PBL中TCR Vβ使用情况的分析表明,HCC患者的T淋巴细胞可能具有受限的免疫反应性,并且Vβ3受限的TIL可能代表抗肿瘤效应细胞。